GPhA Pushes REMS Pay-for, Schedule III Hydrocodone In User Fee Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Generic association had officially been agnostic in the choice between House’s pay-for, which would speed biosimilar petition review, and the Senate provision, which ensures access to REMS products for ANDA development. But a letter to Congress now formally outlines GPhA’s hopes for the user fee conference.
You may also be interested in...
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.
FDA User Fee Hearing Hijacked By US Health Care Reform Arguments
Democrats argue generic competition alone cannot fix drug pricing problem as senators attempt to pull FDA into Obamacare repeal and replace debate.
Generics REMS Hurdles Lowered Somewhat By FDA Protocol Letters
But the U.S. FDA still cannot force brand firms to provide products for bioequivalence testing, which may limit the policy’s ability to remove a barrier that generic firms allege some NDA sponsors use to block competition.